CNC - Three-Year Valuation Estimates (2026–2029)

Based on my metrics ($100B target market cap, 24% historical CAGR, aggressive buybacks, and PE of 17), here is how the next three years could play out:
🟢 Bull Case (Highly Plausible)
The Scenario: Marketplace rate hikes fully cover the higher medical costs by late 2026. Medicare Advantage achieves breakeven, and Medicaid stabilizes. The $2B buyback is executed at depressed prices.
2029 EPS: $10.50 – $12.00
Target Price: At a 17x forward P/E, the stock reaches $178 – $204 per share.

Verdict: This requires flawless execution of their cost-cutting and pricing strategy, but it is achievable given their historical 24% CAGR.

🟡 Base Case (Most Plausible)
The Scenario: Premium increases take slightly longer to catch up with inflation and medical trends. Margins improve, but regulatory scrutiny prevents them from price-gouging the ACA market. EPS recovers steadily but not explosively.
2029 EPS: $7.50 – $8.50 (Aligning with management's long-term goal to return to the $7+ range).

Target Price: At a 15x to 17x forward P/E, the stock reaches $112 – $144 per share.

Verdict: This is the safest bet. It accounts for the reality that healthcare costs rarely drop; they just get passed along with a slight lag.

🔴 Bear Case (Less Plausible, but Risky)
The Scenario: The "sicker risk pool" in the ACA market is permanent. The government pushes back on premium hikes, capping Centene's margins. Medical costs outpace SG&A savings.

2029 EPS: $4.00 – $5.00
Target Price: The market penalizes the lack of growth, compressing the P/E to 12x. Target price languishes around $48 – $60 per share.

Conclusion: The Base Case is the most realistic path over the next 36 months. Management's 2026 guidance is conservative enough to hit, and the structural tailwinds of buybacks provide a hard floor for the EPS.